Nonetheless, the current evidence suggests plasma t‐tau may not be a useful diagnostic blood biomarker for AD, but high concentrations may provide prognostic evidence of incident neurodegeneration, similar to the performance of a t‐tau assay using N‐terminal anti‐tau antibodies which were recently described [156, 157]. This evidence concerns the gene MAPT and Alzheimer disease.